Frequency and timing of multiple skin cancer development in five cohorts.

IF 12.8 1区 医学 Q1 DERMATOLOGY Journal of the American Academy of Dermatology Pub Date : 2025-02-08 DOI:10.1016/j.jaad.2024.12.047
Lee Wheless, Kai-Ping Liao, Siwei Zheng, Yao Li, Lydia Yao, Yaomin Xu, Christopher Madden, Jacqueline Ike, Isabelle T Smith, Dominique Mosley, Sarah Grossarth, Rebecca I Hartman, Otis Wilson, Adriana Hung, Mackenzie R Wehner
{"title":"Frequency and timing of multiple skin cancer development in five cohorts.","authors":"Lee Wheless, Kai-Ping Liao, Siwei Zheng, Yao Li, Lydia Yao, Yaomin Xu, Christopher Madden, Jacqueline Ike, Isabelle T Smith, Dominique Mosley, Sarah Grossarth, Rebecca I Hartman, Otis Wilson, Adriana Hung, Mackenzie R Wehner","doi":"10.1016/j.jaad.2024.12.047","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Many patients will develop more than one skin cancer, however most research to date has examined only case status.</p><p><strong>Objective: </strong>Describe the frequency and timing of the treatment of multiple skin cancers in individual patients over time.</p><p><strong>Methods: </strong>We conducted a longitudinal claims and electronic health record-based cohort study to examine the frequency of skin cancer multiplicity. We used a validated phenotype for counting individual skin cancers.</p><p><strong>Results: </strong>Our combined cohort included 5,508,374 patients and 13,102,123 total skin cancers treated. 43% of patients treated for skin cancer were treated for more than one skin cancer, most within two years of the initial skin cancer. A subset of 3% of patients were treated for 10 or more skin cancers and contributed 22% of all skin cancers treated in the combined cohort LIMITATIONS: High quality data on skin cancer type were not available. Databases and health records are not designed to capture skin cancer multiplicity well CONCLUSIONS: Nearly half of patients treated for skin cancer will develop at least one more. Better data formatting will allow for improved granularity in identifying individuals at high risk for multiple skin cancers and those unlikely to benefit from continued annual surveillance.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8000,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaad.2024.12.047","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Many patients will develop more than one skin cancer, however most research to date has examined only case status.

Objective: Describe the frequency and timing of the treatment of multiple skin cancers in individual patients over time.

Methods: We conducted a longitudinal claims and electronic health record-based cohort study to examine the frequency of skin cancer multiplicity. We used a validated phenotype for counting individual skin cancers.

Results: Our combined cohort included 5,508,374 patients and 13,102,123 total skin cancers treated. 43% of patients treated for skin cancer were treated for more than one skin cancer, most within two years of the initial skin cancer. A subset of 3% of patients were treated for 10 or more skin cancers and contributed 22% of all skin cancers treated in the combined cohort LIMITATIONS: High quality data on skin cancer type were not available. Databases and health records are not designed to capture skin cancer multiplicity well CONCLUSIONS: Nearly half of patients treated for skin cancer will develop at least one more. Better data formatting will allow for improved granularity in identifying individuals at high risk for multiple skin cancers and those unlikely to benefit from continued annual surveillance.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.60
自引率
5.80%
发文量
2023
审稿时长
49 days
期刊介绍: The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.
期刊最新文献
Editorial Board Table of Contents Information for Readers JAAD Case Reports Article List Journal Based CME Instructions and Information
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1